ABL Diagnostics Société anonyme (EPA:ABLD)

Market Cap	87.82M
Revenue (ttm)	5.87M
Net Income (ttm)	285.17K
Shares Out	16.11M
EPS (ttm)	0.02
PE Ratio	272.50
Forward PE	90.83
Dividend	0.05 (0.93%)
Ex-Dividend Date	Jun 27, 2025

Volume	256
Average Volume	122
Open	5.40
Previous Close	5.45
Day's Range	5.40 - 5.40
52-Week Range	2.40 - 8.10
Beta	-0.11
RSI	44.46
Earnings Date	Sep 2, 2025

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and sali...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Chalom Sayada
• Employees: 19
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABLD

Financial Performance

In 2024, EPA:ABLD's revenue was 5.87 million, a decrease of -5.16% compared to the previous year's 6.19 million. Earnings were 285,170, an increase of 424.58%.